BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 18257677)

  • 1. Delivery vehicles for small interfering RNA in vivo.
    de Fougerolles AR
    Hum Gene Ther; 2008 Feb; 19(2):125-32. PubMed ID: 18257677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.
    Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C
    Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNAi for Developing Targeted Therapeutics--CHI's Third Annual Meeting.
    Plane G
    IDrugs; 2010 Jan; 13(1):20-2. PubMed ID: 20024842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes.
    Hossain S; Stanislaus A; Chua MJ; Tada S; Tagawa Y; Chowdhury EH; Akaike T
    J Control Release; 2010 Oct; 147(1):101-8. PubMed ID: 20620182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current issues of RNAi therapeutics delivery and development.
    Haussecker D
    J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivering silence: advancements in developing siRNA therapeutics.
    Novobrantseva TI; Akinc A; Borodovsky A; de Fougerolles A
    Curr Opin Drug Discov Devel; 2008 Mar; 11(2):217-24. PubMed ID: 18283609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
    Singh SK; Hajeri PB
    Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNAi therapeutics: an update on delivery.
    Nguyen T; Menocal EM; Harborth J; Fruehauf JH
    Curr Opin Mol Ther; 2008 Apr; 10(2):158-67. PubMed ID: 18386228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla.
    Meade BR; Dowdy SF
    Discov Med; 2009 Dec; 8(43):253-6. PubMed ID: 20040280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrodynamic delivery protocols.
    Rychahou PG; Evers BM
    Methods Mol Biol; 2010; 623():189-95. PubMed ID: 20217552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo application of RNA interference: from functional genomics to therapeutics.
    Lu PY; Xie F; Woodle MC
    Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using RNAi in the clinic.
    Dev KK
    IDrugs; 2006 Apr; 9(4):279-82. PubMed ID: 16596482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.